Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...

Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine ...

French biotech Transgene (EPA: TNG) has named Simone Steiner as its new chief technical officer, in a move aimed at advancing ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

Docquity, Southeast Asia's largest network of healthcare professionals (HCPs), and global healthcare company Novartis announce a multi-year partnership in Malaysia to address the rise of retinal ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

omnichannel commercial capabilities under its Awareness to Advocacy (A2A) Program, Novartis enhances retinal health education for thousands of ophthalmologists and medical retina doctors across the ...